These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26209955)

  • 1. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug.
    Terranova N; Magni P
    Comput Methods Programs Biomed; 2012 Feb; 105(2):162-74. PubMed ID: 22005012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach.
    Terranova N; Tosca EM; Borella E; Pesenti E; Rocchetti M; Magni P
    J Theor Biol; 2018 Aug; 450():1-14. PubMed ID: 29680449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models.
    Chandra F; Zaks L; Zhu A
    AAPS J; 2019 Jan; 21(2):16. PubMed ID: 30627814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.
    Lestini G; Mentré F; Magni P
    AAPS J; 2016 Sep; 18(5):1233-1243. PubMed ID: 27306546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations.
    Pigatto MC; Roman RM; Carrara L; Buffon A; Magni P; Dalla Costa T
    Eur J Pharm Sci; 2017 Jan; 97():70-78. PubMed ID: 27816627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.
    Magni P; Terranova N; Del Bene F; Germani M; De Nicolao G
    IEEE Trans Biomed Eng; 2012 Aug; 59(8):2161-70. PubMed ID: 22575633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
    Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
    J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.
    Pierrillas PB; Henin E; Ogier J; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    J Pharmacol Exp Ther; 2018 Dec; 367(3):414-424. PubMed ID: 30228112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
    Kogame A; Tagawa Y; Shibata S; Tojo H; Miyamoto M; Tohyama K; Kondo T; Prakash S; Shyu WC; Asahi S
    Drug Metab Dispos; 2013 Apr; 41(4):727-34. PubMed ID: 23298863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.
    Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1303-14. PubMed ID: 27160688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
    Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.
    Mo G; Gibbons F; Schroeder P; Krzyzanski W
    PLoS One; 2014; 9(10):e109747. PubMed ID: 25333487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.